ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2023

Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands.

S W Quist et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.